Delivery Order SPE2DB22D2211-SPE2DB26FRHLD
Award Date 10/31/25
Potential Completion Date 11/3/25
Potential Value $1.7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 14, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $8,424.80 with a firm fixed price structure. This is a non-set-aside competitive award under an Indefinite Delivery Contract arrangement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 15, 2025. As a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,684.96 to supply HEPLISAV-B 20 mcg/0.5 mL syringes on May 27, 2025. The order is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award does not utilize a set-aside designation and was competitively awarded. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $22,056.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply procurement executed under a non-set-aside vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $2,106.20. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 27, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency (DLA) on August 26, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $142,793.60. The contract was awarded under firm fixed-price terms with an ultimate completion date of August 27, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML vaccine syringes with a firm fixed price ceiling value of $5,476.12 and an ultimate completion date of August 25, 2025. This is a non-set-aside, competitively awarded delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitive award utilizes firm fixed pricing and carries no set-aside designation. The contract is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.999 billion prime vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $3,228.20 with a completion date of August 29, 2025. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,527.44 delivery order on September 19, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, non-set-aside contract with a completion date of September 22, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of HEPLISAV-B hepatitis B vaccine (20 mcg/0.5 ml syringes) with a ceiling value of $7,661.90. This is a firm fixed price delivery order with an ultimate completion date of September 15, 2025, and no set-aside designation was used in the competitive award process. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania....